Tag: enrollment

Not for distribution to United States newswire services or for dissemination in the United States

Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- In a powerful show of support for America’s veterans, leading Diagnostic Radiologist Dr. Andrew Gomes has announced the creation of the Dr. Andrew Gomes Scholarship for Veterans, a new opportunity aimed at empowering those who have served in the military and are now pursuing undergraduate degrees. The scholarship, which is awarded through an essay-based application process, is now accepting submissions through March 15, 2026. The winning recipient will be announced on April 15, 2026.